GRI — GRI Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1824293 ·
Last close
$2.04
Market Cap
$3.61M
52W High
$2.97
52W Low
$1.97
ADV30
37,705
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,003,000 | -1,998,000 | 11,339,000 | 11,048,000 | 794,000 |
| Dec 2025 | 0 | — | -2,664,000 | -2,659,000 | 8,666,000 | 8,229,000 | 2,658,000 |
| Sep 2025 | 0 | — | -3,365,000 | -3,359,000 | 4,782,000 | 4,055,000 | 2,789,000 |
| Jun 2025 | 0 | — | -2,897,000 | -2,892,000 | 5,675,000 | 5,122,000 | 2,353,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,186,000
Investing CF
$0
Financing CF
$13,390,000
CapEx
—
Dividends Paid
—
Buybacks
$-1,000
EPS Diluted TTM
$-554.68
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-51,696,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,977,000
Pretax Income TTM
$-11,956,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,977,000 | -11,956,000 | 8,666,000 | 2,658,000 | — | -10,186,000 |
| Dec 2024 | 0 | -8,235,000 | -8,207,000 | 5,739,000 | 1,707,000 | — | -8,611,000 |
| Dec 2023 | 0 | -11,387,000 | -13,037,000 | 2,956,000 | 2,697,000 | — | -8,990,000 |
| Dec 2022 | 0 | -2,239,000 | -3,217,000 | 383,000 | 2,008,000 | — | -1,085,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-5,868,000
OpCashFlow TTM
$0
Assets (Latest)
$5,739,000
Forward EPS
$-2.83
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIXT | BIOXYTRAN, INC | $3.47M | $0.03 | — |
| NXTS | Nexentis Technologies Inc. | $3.78M | $5.17 | — |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | $3.43M | $0.59 | — |
| AZTR | Azitra, Inc. | $3.40M | $0.21 | — |
| PPCB | Propanc Biopharma, Inc. | $3.96M | $1.74 | — |
News headlines (Yahoo Finance, 1h cache)
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
2026-05-18 13:15 · Yahoo
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Im
2026-05-14 12:35 · Yahoo
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
2026-04-08 12:30 · Yahoo
How The Grainger (LSE:GRI) Investment Story Is Evolving As The Narrative Holds Steady
2026-04-04 16:11 · Yahoo
3 Undervalued Small Caps In Global With Recent Insider Activity
2026-04-02 09:40 · Yahoo
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
2026-02-17 14:15 · Yahoo
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
2026-02-09 16:30 · Yahoo
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
2026-02-05 14:15 · Yahoo
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
2026-02-04 13:45 · Yahoo
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
2026-01-28 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.